2022
Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
Damast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.Peer-Reviewed Original ResearchOverall treatment timeHR-CTV DCervical cancerMucosal toxicityMedian high-risk clinical target volumeHigh-risk clinical target volumeCOVID-19 pandemicLocal control outcomesPre-COVID cohortClinical target volumeMagnetic resonance imagingGastrointestinal eventsRetrospective reviewCC patientsEarly outcomesCOVID groupMedian numberInpatient resourcesInterstitial brachytherapyGrade 2Local controlResonance imagingSeparate weeksTarget volumePatients
2021
Benefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy
Li JY, D’Addario J, Tymon-Rosario J, Menderes G, Young MR, Johung K, Ratner E, Minkin MJ, Damast S. Benefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. American Journal Of Clinical Oncology 2021, 44: 143-149. PMID: 33755031, DOI: 10.1097/coc.0000000000000800.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrachytherapyCombined Modality TherapyDyspareuniaFemaleGenital Neoplasms, FemaleHumansInterdisciplinary CommunicationMenopauseMiddle AgedPatient SatisfactionPelvisRadiation InjuriesRadiotherapyRectal NeoplasmsRetrospective StudiesSexual Dysfunction, PhysiologicalSexual HealthTreatment OutcomeVaginal DiseasesWomen's Health ServicesConceptsPelvic radiotherapySexual health clinicsMenopausal symptomsPersistent menopausal symptomsSystemic hormone therapyFemale cancer patientsPatterns of careDilator therapyVaginal estrogenGastrointestinal malignanciesHormone therapyVaginal drynessMedian ageMultidisciplinary careRetrospective reviewFemale patientsTreatment patternsCancer patientsPatient satisfactionSexual symptomsTestosterone creamVaginal lubricantsHealth clinicsSTATA 13.1Patients
2015
Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer
Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer. International Journal Of Gynecological Cancer 2015, 25: 1711-1716. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/igc.0000000000000554.Peer-Reviewed Original ResearchConceptsBrain metastatic diseaseEpithelial ovarian cancerBrain metastasesEndometrial cancerCervical cancerGynecologic cancerSurgical resectionTwo-year overall survival ratesLargest single-institution experienceSingle institution experienceOverall survival rateOverall survival dataMedian survival timeSignificant hazard ratioLong-term survivalHazard ratioMetastatic diseaseOverall survivalImproved survivalRetrospective reviewIntracranial metastasesPalliative carePoor prognosisCancer increasesFactors Predictive